Klin Farmakol Farm. 2008;22(2):55-57

RESISTANCE OF COMMUNITY-ACQUIRED STREPTOCOCCUS AGALACTIAE STRAINS TO MACROLIDE ANTIBIOTICS

Luboslava Čekanová1, MUDr. Vladimír Zbořil CSc2
1 Laboratoře Mikrochem a. s. Olomouc
2 III. interní klinika gastroenterologická, FN Brno-Bohunice

In order to determine the rates of Streptococcus agalactiae resistance to selected antibiotics, 612 Streptococcus agalactiae strains were isolated from vaginal swabs, 156 from upper respiratory tract, and 97 were obtained from urine samples of patients from the community setting between January and December 2006. The bacterial strains isolated were identified using standard microbiological methods. Susceptibility to antibiotics was determined by the disk diffusion method, the phenotype of resistance to macrolide antibiotics was detected by the D-test. The mean values of resistance to erythromycin, clindamycin, and tetracycline were 25.8 %, 24.1 %, and 82.9 %, respectively. The constitutive phenotype of resistance (cMLSB), inducible phenotype (iMLSB), and efflux (M phenotype) mean values were 79.8 %, 13.6 %, and 6.6 %, respectively. The data obtained confirm the problem of resistance to macrolides and lincosamides in Streptococcus agalactiae species in the community setting. The MLSB resistance phenotype was found in 93.4 % of all erythromycin-resistant strains, which in the case of patients allergic to penicillins and cephalosporines poses a therapeutic challenge.

Keywords: Key words: Streptococcus agalactiae, community setting, antibiotic resistance.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čekanová L, Zbořil V. RESISTANCE OF COMMUNITY-ACQUIRED STREPTOCOCCUS AGALACTIAE STRAINS TO MACROLIDE ANTIBIOTICS. Klin Farmakol Farm. 2008;22(2):55-57.
Download citation

References

  1. Andrews JI, Diekema DJ, Hunter SK, et al. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am J Obstet Gynecol 2000; 183: 859-862. Go to original source... Go to PubMed...
  2. Manning SD, Pearlman MD, Tallman P, Pierson CL, Foxman B. Frequency of antibiotic resistance among group B Streptococcus isolated from healthy college students. Clin Infect Dis 2001; 33: 137-139. Go to original source... Go to PubMed...
  3. Murdoch DR, Reller LB. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10year perspective. Antimicrob Agents Chemother 2001; 45: 3623-3624. Go to original source... Go to PubMed...
  4. Lopardo HA, Vidal P, Jeric P, et al. Six-month multicenter study on invasive infections due to group B streptococci in Argentina. J Clin Microbiol 2003; 41: 4688-4694. Go to original source... Go to PubMed...
  5. Schoening TE, Wagner J, Arvand M. Prevalence of erythromycin and clindamycin resistance among Streptococcus agalactiae isolates in Germany. Clin Microbiol Infect 2005; 11: 579-582. Go to original source... Go to PubMed...
  6. Betriu C, Culebras E, Gómez M, et al. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother 2003; 47: 1112-1114. Go to original source... Go to PubMed...
  7. Figueira-Coelho J, Ramirez M, Salgado MJ, Melo-Cristino J. Streptococcus agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, serotype distribution, and clonal analysis of macrolide-resistant isolates. Microb Drug Resist 2004; 10: 31-36. Go to original source... Go to PubMed...
  8. Seppäla H, Nissinen A, Yu Q, et al. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother 1993; 32: 885-891. Go to original source... Go to PubMed...
  9. Urbášková P, Jakubů V, Melter O. Analýza rezistence Streptococcus pyogenes k antibiotikům ze skupiny makrolidů, linkosamidů a streptograminuB (MLSB). Zprávy CEM (SZÚ, Praha) 2004; 13: 28-29.
  10. Arpin C, Daube H, Tessier F, Quentin C. Presence of mefA and mefE genes in Streptococcus agalactiae. Antimicrob Agents Chemother. 1999; 43: 944-946. Go to original source... Go to PubMed...
  11. Jakubů V, Urbášková P. Fenotypy rezistence na makrolidová antibiotika u Streptococcus pyogenes. Zprávy CEM (SZÚ Praha) 2000; 9: 499-500.
  12. Urbášková P. Rezistence bakterií k antibiotikům - vybrané metody. Praha Trios, 1998.
  13. De Mouy D, Cavallo JD, Leclercq R, Fabre R, The Aforcopi-Bio Network. Antibiotic susceptibility and mechanism of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob Agents Chemother 2001; 45: 2400-2402. Go to original source... Go to PubMed...
  14. Rouse DJ, Andrews WW, Lin FY, et al. Antibiotic susceptibility profile of group B Streptococcus acquired vertically. Obstet Gynecol 1998; 92: 931-934. Go to original source... Go to PubMed...
  15. Borchardt SM, DeBusscher JH, Tallman PA, et al. Frequency of antimicrobial resistance among invasive and colonizing group B streptococcal isolates. BMC Infect Dis 2006; 6: 57-64. Go to original source... Go to PubMed...
  16. DiPersio LP, DiPersio JR. High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus. Diagn Microbiol Infect Dis 2006; 54: 79-82. Go to original source... Go to PubMed...
  17. Culebras E, Rodriguez-Avial I, Betriu C, Redondo M, Picazo JJ. Macrolide and tetracycline resistance and molecular relationships of clinical strains of Streptococcus agalactiae. Antimicrob Agents Chemother 2002; 46: 1574-1576. Go to original source... Go to PubMed...
  18. Čekanová L, Kolář M. Vývoj rezistence komunitních respiračních patogenů k antimikrobním přípravkům v olomouckém regionu. Interní Med. 2007; 9: 405-407.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.